Rocket Pharmaceuticals, Inc.
Infantile Malignant Osteopetrosis (IMO)
In January 2022, Rocket disclosed plans return the program back to academic collaborators in order to reallocate resources to Rocket’s pipeline.
In January 2022, Rocket disclosed plans return the program back to academic collaborators in order to reallocate resources to Rocket’s pipeline.